[go: up one dir, main page]

WO2005110478A3 - Polytherapie destinee a traiter des troubles fibreux - Google Patents

Polytherapie destinee a traiter des troubles fibreux

Info

Publication number
WO2005110478A3
WO2005110478A3 PCT/US2005/012579 US2005012579W WO2005110478A3 WO 2005110478 A3 WO2005110478 A3 WO 2005110478A3 US 2005012579 W US2005012579 W US 2005012579W WO 2005110478 A3 WO2005110478 A3 WO 2005110478A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
pirfenidone
antagonist
disease
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/012579
Other languages
English (en)
Other versions
WO2005110478A2 (fr
Inventor
Lawrence M Blatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of WO2005110478A2 publication Critical patent/WO2005110478A2/fr
Publication of WO2005110478A3 publication Critical patent/WO2005110478A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés permettant de traiter des maladies fibreuses, notamment la fibrose pulmonaire, la fibrose pulmonaire idiopathique (IPF), la fibrose pulmonaire à partir d'une étiologie connue, la fibrose du foie, la fibrose cardiaque et la fibrose du rein. Ces procédés consistent généralement à administrer à un individu souffrant d'une maladie fibreuse, (i) de la pirfénidone, un analogue de pirfénidone ou un agoniste du récepteur d'interféron de type II, et (ii) un antagoniste TGF-ß ou un antagoniste du récepteur d'endothéline simultanément, dans une quantité efficace pour améliorer l'évolution clinique de la maladie. Cette invention concerne également un procédé permettant de traiter un trouble fibreux par administration à un individu de (i) pirfénidone, un analogue de pirfénidone ou un agoniste du récepteur d'interféron de type II, et (ii) un antagoniste TGF-ß ou un antagoniste du récepteur d'endothéline dans des quantités efficaces en synergie afin d'améliorer l'évolution clinique de la maladie.
PCT/US2005/012579 2004-04-13 2005-04-13 Polytherapie destinee a traiter des troubles fibreux Ceased WO2005110478A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56195004P 2004-04-13 2004-04-13
US56218404P 2004-04-13 2004-04-13
US56194004P 2004-04-13 2004-04-13
US56209104P 2004-04-13 2004-04-13
US60/562,184 2004-04-13
US60/561,940 2004-04-13
US60/562,091 2004-04-13
US60/561,950 2004-04-13

Publications (2)

Publication Number Publication Date
WO2005110478A2 WO2005110478A2 (fr) 2005-11-24
WO2005110478A3 true WO2005110478A3 (fr) 2006-07-13

Family

ID=35394681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012579 Ceased WO2005110478A2 (fr) 2004-04-13 2005-04-13 Polytherapie destinee a traiter des troubles fibreux

Country Status (1)

Country Link
WO (1) WO2005110478A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
WO2010065755A1 (fr) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Pyridinones deutérées
JP2014507474A (ja) 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
MX2013013752A (es) * 2011-05-25 2014-08-01 Intermune Inc Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
EP4422634A2 (fr) * 2021-10-28 2024-09-04 Association Institut de Myologie Nouvelle utilisation thérapeutique d'antagonistes du récepteur de l'endothéline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SELMAN M. ET AL.: "Idiopathic Pulmonary Fibrosis: Pathogenesis and Therapeutic Approaches", DRUGS, vol. 64, no. 4, February 2004 (2004-02-01), pages 405 - 430, XP008070575 *
SIMMS R.W. ET AL.: "Cytokine Directed Therapy in Scleroderma: Rationale, Current Status, and the Future", CURR. OPIN. RHEUMAT., vol. 14, 2002, pages 717 - 722, XP008070574 *

Also Published As

Publication number Publication date
WO2005110478A2 (fr) 2005-11-24

Similar Documents

Publication Publication Date Title
Girgis et al. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
WO2005070462A3 (fr) Compositions comprenant de la (s)-amlodipine et un bloqueur du recepteur de l'angiotensine, et leurs methodes d'utilisation
Langleben et al. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study
WO2004028521A3 (fr) Composes organiques
WO2006086456A3 (fr) Combinaison de composes organiques
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
WO2006031922A3 (fr) Analogues d'hormones thyroidiennes et procedes d'utilisation correspondants
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2006037031A3 (fr) Formulations et procedes destines au traitement de maladies inflammatoires
WO2006086488A3 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
TN2011000228A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
US11883407B2 (en) Medicament for the treatment of chronic cough
WO2005030187A3 (fr) Iloprost en polytherapies pour le traitement de l'hypertension arterielle pulmonaire
WO2005110478A3 (fr) Polytherapie destinee a traiter des troubles fibreux
WO2007120270A3 (fr) Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
EP1413201A3 (fr) Utilisation des antagonistes des cannaux sodiques pour contrôler les ectoparasites dans les animaux homeothermiques
WO2005082893A3 (fr) Antagonistes du recepteur d'histamine h3, leur preparation et leurs utilisations therapeutiques
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2005011590A3 (fr) Compositions et procedes pour le retablissement de la sensibilite au traitement par antagonistes vis-a-vis de her2
WO2005079766A3 (fr) Polytherapie
Fattinger et al. Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine
WO2006045314A3 (fr) Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique
WO2004026837A3 (fr) Antagonistes du recepteur h3 d'histamine, preparation et applications therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase